Healios K.K. Pursues Conditional Approval for Ischemic Stroke Treatment in Japan

An update from Healios KK ( (JP:4593) ) is now available.

Healios K.K. has announced its decision to file for conditional and time-limited approval for its ischemic stroke treatment, HLCM051, in Japan. Despite not meeting the primary endpoint in the TREASURE study, the treatment showed significant improvements in patients’ daily living activities and independence. The company plans to leverage a registry system for post-marketing studies, aiming for a streamlined path to full approval. This approach aligns with Japan’s regulatory guidance and involves collaboration with prominent universities and medical institutions to ensure effective data collection and analysis.

More about Healios KK

Healios K.K. operates in the regenerative medicine industry, focusing on developing somatic stem cell products. Its primary products include HLCM051, which targets conditions like ischemic stroke and acute respiratory distress syndrome. The company is actively engaged in the Japanese market and collaborates with various academic and medical institutions.

YTD Price Performance: 65.54%

Average Trading Volume: 3,282,925

Technical Sentiment Signal: Sell

Current Market Cap: Yen29.73B

Find detailed analytics on 4593 stock on TipRanks’ Stock Analysis page.